214 related articles for article (PubMed ID: 35177053)
1. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.
Escobar C; Morales C; Capel M; Simón S; Pérez-Alcántara F; Pomares E
BMC Health Serv Res; 2022 Feb; 22(1):217. PubMed ID: 35177053
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
McEwan P; Morgan AR; Boyce R; Bergenheim K; Gause-Nilsson IAM; Bhatt DL; Leiter LA; Johansson PA; Mosenzon O; Cahn A; Wilding JPH
Diabetes Obes Metab; 2021 Apr; 23(4):1020-1029. PubMed ID: 33368855
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
[TBL] [Abstract][Full Text] [Related]
5. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
Abad Paniagua EJ; Casado Escribano P; Fernández Rodriguez JM; Morales Escobar FJ; Betegón Nicolás L; Sánchez-Covisa J; Brosa M
Aten Primaria; 2015 Oct; 47(8):505-13. PubMed ID: 25555492
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
van Haalen HG; Pompen M; Bergenheim K; McEwan P; Townsend R; Roudaut M
Clin Drug Investig; 2014 Feb; 34(2):135-46. PubMed ID: 24243529
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Elsisi GH; Anwar MM; Khattab M; Elebrashy I; Wafa A; Elhadad H; Awad M; Carapinha JL
J Med Econ; 2020 Aug; 23(8):908-914. PubMed ID: 32364032
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Furtado RHM; Raz I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Aylward P; Dalby AJ; Dellborg M; Dimulescu D; Nicolau JC; Oude Ophuis AJM; Cahn A; Mosenzon O; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2022 May; 145(21):1581-1591. PubMed ID: 35510542
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
Gu S; Mu Y; Zhai S; Zeng Y; Zhen X; Dong H
PLoS One; 2016; 11(11):e0165629. PubMed ID: 27806087
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Norhammar A; Bodegård J; Nyström T; Thuresson M; Nathanson D; Eriksson JW
Diabetes Obes Metab; 2019 May; 21(5):1136-1145. PubMed ID: 30609272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
